buPROPion Hydrochloride Extended-Release Tablets — Class II drug recall D-0222-2024
Ongoing recall by Rising Pharma Holding, Inc., reported 2024-01-17, distributed nationwide. Presence of Foreign Tablets/Capsules
| Recall number | D-0222-2024 |
|---|---|
| Product type | Drug |
| Classification | Class II |
| Status | Ongoing |
| Voluntary or mandated | Voluntary |
| Recalling firm | Rising Pharma Holding, Inc., East Brunswick, NJ, United States |
| Recall initiated | 2023-12-29 |
| Classified | 2024-01-11 |
| Reported by FDA | 2024-01-17 |
| Distributed | Nationwide (US) |
| Quantity | 47,976 bottles |
| NDC | 16571-0862, 16571-0862-03, 16571-0862-09, 16571-0862-10, 16571-0862-12, 16571-0862-50, 16571-0863, 16571-0863-03, 16571-0863-09, 16571-0863-10, 16571-0863-50 |
| Lot numbers | BPA123098A |
| Expiration dates | 2025-06 |
Product
buPROPion Hydrochloride Extended-Release Tablets, USP (XL) 150mg, 30-count bottles, Rx Only, Manufactured for: Rising Pharma Holdings, Inc. East Brunswick, NJ 08816 Manufactured by: Graviti Pharmaceuticals Pvt. Ltd. Telangana - 502307, INDIA, NDC 16571-862-03
Reason for recall
Presence of Foreign Tablets/Capsules
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-0222-2024. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.